Enteral Feeding Formulas Market by Product (Standard Formula, Disease Specific, Diabetic Formula, Renal Formula, Hepatic Formula, Pulmonary Formula, and Other), Stage ( Adult and Pediatric), Application (Oncology, Gastrointestinal Diseases, Neurological Disorders, Diabetes, and Other), End-user (Hospitals, Long Term Care Facilities, Nursing Homes, Assisted Living Facilities, and Home Care Agencies & Hospices): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026466 | Pages: 100 | Industry: Pharmaceuticals | Date: Sep 2022 | Type: Global

The market crossed the US$ 5.69 billion mark in 2022 and is expected to hit US$ 10.71 billion by 2030, recording a CAGR of 8.2% during the forecast period.

Disease-specific formula segment has been significantly growing with the high adoption of enteral feeding formula.

The rising prevalence of gastrointestinal disorders such as Crohn’s disease, cystic fibrosis, pancreatitis, head and neck cancer, and cerebrovascular accidents will propel the demand for the enteral feeding formula market. Nutritional support is critical in the primary and adjunctive management of many GI tract diseases. The market is expected to grow significantly with increased adoption and product development. Disease-specific formula segment is the fastest growing segment in the product category. The diabetes-specific formula has shown a reduced postprandial rise in blood glucose. Increased incidences of diabetes patients worldwide will propel the change in the forecast period.

Within the report, the market is segmented into product, stage, application, and end-user. By product, the market is segmented into the standard formula, disease-specific, diabetic formula, renal formula, hepatic formula, pulmonary formula, and others. By stage, the market is segmented into adults and pediatrics. By end users, it is segmented into hospitals, nursing homes, long-term care facilities, assisted living facilities, home care agencies & hospices. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Get more information on this report :

The enteral feeding market is expected to grow due to the prevalence of chronic disorders.

Enteral feeding is a form of nutrition delivered into the digestive system as a liquid. It is beneficial for people who are unable to meet their nutritional needs. The formula is either fed with a tube or orally. The medical professional usually prescribe enteral feeding for chronically ill patients. The enteral feeding formula market is driven by rising metabolic and chronic disease prevalence, increased patient care expenditure, and a growing geriatric population. Moreover, the rising number of premature births increases nutritional deficiency, protein deficiency, and micronutrients in infants and pregnant women.

Rising incidence of anorexia nervosa among the younger population.

Anorexia nervosa is an eating disorder characterized by abnormally low body weight, fear of increased weight, and a distorted perception of weight gain. People with this eating disorder have a high need to control their weight and body shape. They take extreme measures to prevent it. Teenagers have a higher risk of developing this disorder because of the body changes during puberty as they face increased peer pressure and are sensitive to body criticism. People with this eating disorder can get extremely malnourished, damaging vital organs such as the brain, heart, and kidneys. The damage from extreme malnutrition cannot be reversed even though anorexia is in control. In patients with severe undernutrition, it is becoming necessary to use oral nutrition support and artificial nutrition, besides ordinary food; enteral nutrition should be a preferred feeding route if there is an accessible gastrointestinal tract.

Recent strategic developments in the enteral feeding formula market

The enteral feeding formulas market has undergone several significant consequences, and a few of these have been mentioned below:

  • In April 2022, Fresenius Kabi launched a new enteral nutrition product app. The Enteral Nutrition Product App makes accessing detailed product information easier and includes a quick comparison tool to compare nutritional values against reference nutrient intakes.
  • In July 2019, Abbott launched the PediaSure Harvest product and Ensured Harvest, a new blend of real-food ingredients from sources such as mango, spinach, carrot, pumpkin, and banana, to fulfill the demand for nourishing food blend formulas for tube-fed patients.

Several players drive the enteral feeding market by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Abbott Laboratories; Braun Melsungen AG; Danone SA (Nutricia); Fresenius Kabi AG; Global Health Product Inc.; Reckitt Benckiser Group plc.; Meiji Holdings Co. Ltd; Nestle SA; Trovita Health Science; Victus Inc. are among the prominent players operating in the market.

The target audience for the report:

  • Raw material providers
  • Venture capitalists, private equity firms, and start-up companies
  • Research institutes, organizations, and consulting companies
  • Healthcare facilities
  • Hospitals

Scope of the report:

In this report, the market has been segmented based on:

  • Product :
    • Standard Formula
    • Disease-specific
    • Diabetic Formula
    • Renal Formula
    • Hepatic Formula
    • Pulmonary Formula
    • Other
  •  Stage:
    • Adults
    • Pediatric
  • Application:
    • Oncology
    • Gastrointestinal Diseases
    • Neurological Disorders
    • Diabetes
    • Other Applications
  •  End User :
    • Hospitals
    • Long Term Care Facilities
    • Nursing Homes
    • Assisted Living Facilities
    • Home Care Agencies & Hospices
  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America (SCAM)
    • Middle East & Africa (MEA)
  • Companies Profiled
    • Abbott Laboratories
    • B. Braun Melsungen AG
    • Danone SA (Nutricia)
    • Fresenius SE & Co. KgaA (Fresenius Kabi AG)
    • Global Health Product Inc.
    • Reckitt Benckiser Group plc. (Mead Johnson)
    • Meiji Holdings Co. Ltd
    • Nestle SA
    • Trovita Health Science
    • Victus Inc.

Companies profiled
- Abbott Laboratories
- B. Braun Melsungen AG
- Danone SA (Nutricia)
- Fresenius SE & Co. KgaA (Fresenius Kabi AG)
- Global Health Product Inc.
- Reckitt Benckiser Group plc. (Mead Johnson)
- Meiji Holdings Co. Ltd
- Nestle SA
- Trovita Health Science
- Victus Inc.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000